Takeda Pharmaceutical Co (4502) Price & Analysis

Compare

6 Followers

4502 Stock Chart & Stats

¥4222.00

-¥15.00(-0.36%)

At close: Jan 08 4:00 PM EST

¥4222.00

-¥15.00(-0.36%)

Day’s Range― - ―

52-Week Range¥3,916.00 - ¥4,678.00

Previous CloseN/A

Volume3.70M

Average Volume (3M)4.35M

Market Cap

¥7.30T

Enterprise Value¥10.78T

Total Cash (Recent Filing)¥739.68B

Total Debt (Recent Filing)¥4.65T

Price to Earnings (P/E)213.3

Beta0.44

Next Earnings

Jan 29, 2026

EPS Estimate

53.2

Next Dividend Ex-DateN/A

Dividend Yield4.3%

Share Statistics

EPS (TTM)-7.83

Shares Outstanding1,590,985,800

10 Day Avg. Volume4,483,280

30 Day Avg. Volume4,345,693

Financial Highlights & Ratios

PEG Ratio-2.51

Price to Book (P/B)1.00

Price to Sales (P/S)1.52

P/FCF Ratio9.15

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥5,033.02

Price Target Upside19.21% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

EPS Forecast (FY)115.98

Revenue Forecast (FY)¥4.51T

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessFavorable Phase III results for orexin receptor agonist oveporexton for NT1 presented, showing significant improvement across NT1 symptoms.

Market PerformanceEntyvio continues to grow faster than the market, withstanding biosimilar step edits and branded competition.

Product DevelopmentSmooth progress on the late-stage development product is positive, with no serious treatment-related adverse events reported.

Bears Say

Government Pricing InitiativesEntyvio faces potential pricing headwinds via two government initiatives: MFN and IRA.

Pricing PressureMFN poses a threat not just because of its direct implications, but also because of the way in which prices are determined for 340b.

Takeda Pharmaceutical Co News

Leerink says Takeda results signal positive readthrough for Alumis

Leerink analyst Thomas J. Smith notes that Takeda (TAK) announced positive topline results from the Phase 3 LATITUDE...

5d ago

TAK

ALMS

Alumis price target raised to $20 from $14 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Alumis (ALMS) to $20 from $14 and...

5d ago

TAK

ALMS

Takeda announces zasocitinib studies met primary, secondary endpoints

Takeda (TAK) announced topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled...

5d ago

TAK

Protagonist, Takeda present longer-term data at ASH 2025 on rusfertide

Protagonist Therapeutics (PTGX) and Takeda (TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study...

16d ago

TAK

PTGX

Takeda’s Oral TYK2 Inhibitor Zasocitinib Delivers Strong Phase 3 Psoriasis Results

Takeda Pharmaceutical Co ( ($JP:4502) ) just unveiled an update. Takeda reported positive topline results from two pivotal...

5d ago

Takeda and Protagonist Showcase Promising Rusfertide Results at ASH 2025

Takeda Pharmaceutical Co ( ($JP:4502) ) has provided an announcement. Takeda and Protagonist Therapeutics presented new 52-week data...

15d ago

FDA investigating death following Adzynma treatment

In a safety communication date November 21, the FDA stated: “Since approval, the Food and Drug Administration has...

1M ago

TAK

Takeda Pharmaceutical: Strategic Growth and Favorable Positioning Drive Buy Rating

Takeda Pharmaceutical Company, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Nedelcovych...

1M ago

TAK

Evercore disagrees with Street reaction on Alkermes

Evercore ISI said the firm disagrees with the Street reaction on Alkermes (ALKS), adding that the “Street has...

1M ago

TAK

ALKS

Alkermes initiated with a Buy at Truist

Truist initiated coverage of Alkermes (ALKS) with a Buy rating and $50 price target. The firm values the...

1M ago

TAK

ALKS

Takeda presents interim data from Phase 1b study of mezagitamab

Takeda (TAK) announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab, an anti-CD38...

2M ago

TAK

Takeda completes seven-year Phase 3 TIDES trial of Qdenga

Takeda (TAK) announced the completion of the seven-year Phase 3 TIDES trial evaluating its dengue vaccine, Qdenga. These...

2M ago

TAK

Takeda Pharmaceutical Reports Decline in Revenue and Profit

Takeda Pharmaceutical Co ( ($TKPHF) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

Takeda Revises Financial Forecast for FY2025 Amid Strategic Shifts

Takeda Pharmaceutical Co ( ($JP:4502) ) has provided an update. Takeda Pharmaceutical Co has revised its financial forecast...

2M ago

4502 FAQ

What was Takeda Pharmaceutical Co’s price range in the past 12 months?

Takeda Pharmaceutical Co lowest stock price was ¥3916.00 and its highest was ¥4678.00 in the past 12 months.

What is Takeda Pharmaceutical Co’s market cap?

Takeda Pharmaceutical Co’s market cap is ¥7.30T.

When is Takeda Pharmaceutical Co’s upcoming earnings report date?

Takeda Pharmaceutical Co’s upcoming earnings report date is Jan 29, 2026 which is in 37 days.

How were Takeda Pharmaceutical Co’s earnings last quarter?

Takeda Pharmaceutical Co released its earnings results on Oct 30, 2025. The company reported -¥7.83 earnings per share for the quarter, missing the consensus estimate of ¥20.735 by -¥28.565.

Is Takeda Pharmaceutical Co overvalued?

According to Wall Street analysts Takeda Pharmaceutical Co’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Takeda Pharmaceutical Co pay dividends?

Takeda Pharmaceutical Co pays a Semiannually dividend of ¥100 which represents an annual dividend yield of 4.3%. See more information on Takeda Pharmaceutical Co dividends here

What is Takeda Pharmaceutical Co’s EPS estimate?

Takeda Pharmaceutical Co’s EPS estimate is 53.2.

How many shares outstanding does Takeda Pharmaceutical Co have?

Takeda Pharmaceutical Co has 1,590,985,800 shares outstanding.

What happened to Takeda Pharmaceutical Co’s price movement after its last earnings report?

Takeda Pharmaceutical Co reported an EPS of -¥7.83 in its last earnings report, missing expectations of ¥20.735. Following the earnings report the stock price went up 0.543%.

Which hedge fund is a major shareholder of Takeda Pharmaceutical Co?

Currently, no hedge funds are holding shares in JP:4502

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Takeda Pharmaceutical Co

Takeda Pharmaceutical Company Limited, headquartered in Tokyo, Japan, is a global biopharmaceutical leader focused on the research, development, manufacturing, and marketing of innovative medicines. The company operates in several therapeutic areas, including oncology, gastroenterology, neuroscience, rare diseases, and vaccines. Takeda's core products include treatments for various cancers, gastrointestinal disorders, and rare diseases, alongside a growing portfolio of vaccines and biologics.

Takeda Pharmaceutical Co (4502) Earnings & Revenues

Historic Earnings Reports

4502 Company Deck

4502 Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflected a mixed financial performance with strong cash flow and pipeline advancements but was overshadowed by significant challenges such as the VYVANSE generic impact, ENTYVIO's slower growth, and foreign exchange headwinds. The partnership with Innovent Biologics provides a positive outlook for the oncology pipeline, but current financial pressures remain a concern.View all JP:4502 earnings summaries

4502 Stock 12 Month Forecast

Average Price Target

¥5,033.02

▲(19.21% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3938":"¥3,938","5601":"¥5,601","4353.75":"¥4,353.8","4769.5":"¥4,769.5","5185.25":"¥5,185.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5600.628930728,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥5.60K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5033.018867844,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥5.03K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4499.999999928,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥4.50K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3938,4353.75,4769.5,5185.25,5601],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4153,4264.356071594461,4375.712143188923,4487.068214783385,4598.424286377846,4709.780357972308,4821.136429566769,4932.492501161231,5043.848572755693,5155.204644350154,5266.560715944615,5377.916787539078,5489.272859133539,{"y":5600.628930728,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4153,4220.693759064923,4288.387518129846,4356.081277194769,4423.775036259693,4491.468795324616,4559.162554389539,4626.856313454461,4694.550072519384,4762.243831584307,4829.9375906492305,4897.631349714154,4965.325108779077,{"y":5033.018867844,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4153,4179.692307686769,4206.3846153735385,4233.076923060307,4259.769230747077,4286.461538433846,4313.1538461206155,4339.846153807384,4366.538461494154,4393.230769180923,4419.9230768676925,4446.615384554461,4473.307692241231,{"y":4499.999999928,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3967.512,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3939.774,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3999.076,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4025.857,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4145.419,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4407.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4273.487,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4179.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4294.991,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4121.979,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4368.301,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4260,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4153,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >